TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Qualigen Therapeutics ( (QLGN) ).
On July 23, 2025, Qualigen Therapeutics received a notice from Nasdaq indicating non-compliance with the $2.5 million stockholders’ equity requirement. However, by July 24, 2025, Nasdaq granted an extension after Qualigen filed its quarterly report and completed a $4.5 million private placement, demonstrating compliance on a pro forma basis. The company submitted a compliance plan for the next 12 months, which Nasdaq accepted, but there is no assurance of maintaining compliance with all listing standards.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for cancer and infectious diseases. Its pipeline includes QN-302, a selective G-quadruplex inhibitor for tumor types like pancreatic cancer; QN-247, targeting nucleolin for hematologic malignancies; and small-molecule RAS oncogene protein-protein interaction inhibitors, addressing high unmet medical needs with potential orphan drug designation.
Average Trading Volume: 838,548
Technical Sentiment Signal: Sell
Current Market Cap: $4.58M
See more insights into QLGN stock on TipRanks’ Stock Analysis page.